Deerfield, Ill.-based Baxter International showcased enhancements to its FLOSEAL and TISSEEL hemostatic agents at the Association of periOperative Registered Nurses Global Surgical Conference and Expo in Boston, held from April 1 to April 5, 2017.
Here are five highlights:
1. FLOSEAL Full Sterile Preparation is an enhanced design for preparing Baxter's FLOSEAL Hemostatic Matrix, which is intended to control bleeding during cardiac and spinal surgeries.
2. FLOSEAL Full Sterile Preparation has the same indications and formulation as FLOSEAL and is easily prepared by a single person in fewer steps.
3. Europeans already have access to the new design, which they note offers greater control over preparation consistency and allows independent preparation within the surgical team.
4. Journal of Medical Economics published two studies highlighting FLOSEAL Hemostatic Matrix's potential costs savings for cardiac and spinal surgeries. Researches discovered potential hospital cost savings of $151 per major and $574 per severe spinal surgery when using FLOSEAL, compared to using Somerville, N.J.-based Ethicon's SURGIFLO.
5. Baxter's TISSEEL is designed to control bleeding, including in patients using heparin to subdue blood clot risk. The company revealed a new applicator that snaps and locks to the syringe, creating a more secure attachment.